Ac Immune (NASDAQ: ACIU)
Ac Immune Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ac Immune Company Info
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
News & Analysis
Why Shares of AC Immune Jumped This Week
The company's stock rose after the FDA granted a Fast Track Designation to its Alzheimer's disease vaccine candidate.
Here's Why AC Immune Stock Is Surging Today
MIxed results for the company's Alzheimer's disease candidate are good enough for the market today.
Why AC Immune Stock Surged Today
Researchers are excited about the potential of the biotech's investigational Alzheimer's vaccine.
Why AC Immune Stock Is Crashing Today
AC Immune's experimental Alzheimer's-disease drug missed the mark in a midstage trial.
Here's Why AC Immune Jumped Higher Today
Investors are excited about the company advancing its Alzheimer's disease vaccine, but caution is warranted.
Why AC Immune SA Is Imploding
Shares crater after the company provides investors with terrible clinical news.
Here's Why AC Immune SA Rose as Much as 21.6% Today
The early-stage biopharma announced more details about a share offering to raise much-needed capital.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.